These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 30579151)
41. Assessment of early thromboelastometric variables from extrinsically activated assays with and without aprotinin for rapid detection of fibrinolysis. Dirkmann D; Görlinger K; Peters J Anesth Analg; 2014 Sep; 119(3):533-542. PubMed ID: 24977914 [TBL] [Abstract][Full Text] [Related]
42. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters. Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650 [TBL] [Abstract][Full Text] [Related]
43. Assessment of Functional Fibrinolysis in Cord Blood Using Modified Thromboelastography. Sidlik R; Strauss T; Morag I; Shenkman B; Tamarin I; Lubetsky A; Livnat T; Kenet G Pediatr Blood Cancer; 2016 May; 63(5):839-43. PubMed ID: 26749087 [TBL] [Abstract][Full Text] [Related]
44. MASP-1 of the complement system alters fibrinolytic behaviour of blood clots. Jenny L; Noser D; Larsen JB; Dobó J; Gál P; Pál G; Schroeder V Mol Immunol; 2019 Oct; 114():1-9. PubMed ID: 31325724 [TBL] [Abstract][Full Text] [Related]
45. Coagulation profile of COVID-19 patients admitted to the ICU: An exploratory study. Corrêa TD; Cordioli RL; Campos Guerra JC; Caldin da Silva B; Dos Reis Rodrigues R; de Souza GM; Midega TD; Campos NS; Carneiro BV; Campos FND; Guimarães HP; de Matos GFJ; de Aranda VF; Rolim Ferraz LJ PLoS One; 2020; 15(12):e0243604. PubMed ID: 33320874 [TBL] [Abstract][Full Text] [Related]
46. The contribution of activated factor XIII to fibrinolytic resistance in experimental pulmonary embolism. Reed GL; Houng AK Circulation; 1999 Jan; 99(2):299-304. PubMed ID: 9892598 [TBL] [Abstract][Full Text] [Related]
47. The in vivo effect of fibrinogen and factor XIII on clot formation and fibrinolysis in Glanzmann's thrombasthenia. Shenkman B; Livnat T; Misgav M; Budnik I; Einav Y; Martinowitz U Platelets; 2012; 23(8):604-10. PubMed ID: 22273510 [TBL] [Abstract][Full Text] [Related]
48. ROTEM diagnostic capacity for measuring fibrinolysis in neonatal sepsis. Lampridou M; Sokou R; Tsantes AG; Theodoraki M; Konstantinidi A; Ioakeimidis G; Bonovas S; Politou M; Valsami S; Iliodromiti Z; Boutsikou T; Iacovidou N; Nikolopoulos G; Tsantes AE Thromb Res; 2020 Aug; 192():103-108. PubMed ID: 32464452 [TBL] [Abstract][Full Text] [Related]
49. Contact activation prolongs clot lysis time in human plasma: role of thrombin-activatable fibrinolysis inhibitor and Factor XIII. Nielsen VG; Steenwyk BL; Gurley WQ J Heart Lung Transplant; 2006 Oct; 25(10):1247-52. PubMed ID: 17045938 [TBL] [Abstract][Full Text] [Related]
50. The S100A10 Pathway Mediates an Occult Hyperfibrinolytic Subtype in Trauma Patients. Gall LS; Vulliamy P; Gillespie S; Jones TF; Pierre RSJ; Breukers SE; Gaarder C; Juffermans NP; Maegele M; Stensballe J; Johansson PI; Davenport RA; Brohi K; Ann Surg; 2019 Jun; 269(6):1184-1191. PubMed ID: 31082919 [TBL] [Abstract][Full Text] [Related]
51. Fibrinolysis is impaired in patients with primary immune thrombocytopenia. Schramm T; Rast J; Mehic D; Reitsma SE; de Moreuil C; Fillitz M; Quehenberger P; de Laat B; Wolberg AS; Ay C; Pabinger I; Gebhart J J Thromb Haemost; 2024 Nov; 22(11):3209-3220. PubMed ID: 39214313 [TBL] [Abstract][Full Text] [Related]
52. A systematic review on the rotational thrombelastometry (ROTEM®) values for the diagnosis of coagulopathy, prediction and guidance of blood transfusion and prediction of mortality in trauma patients. Veigas PV; Callum J; Rizoli S; Nascimento B; da Luz LT Scand J Trauma Resusc Emerg Med; 2016 Oct; 24(1):114. PubMed ID: 27716278 [TBL] [Abstract][Full Text] [Related]
53. Exposing the bidirectional effects of alcohol on coagulation in trauma: Impaired clot formation and decreased fibrinolysis in rotational thromboelastometry. Howard BM; Kornblith LZ; Redick BJ; Conroy AS; Nelson MF; Calfee CS; Callcut RA; Cohen MJ J Trauma Acute Care Surg; 2018 Jan; 84(1):97-103. PubMed ID: 29267182 [TBL] [Abstract][Full Text] [Related]
54. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis. Colucci M; Binetti BM; Branca MG; Clerici C; Morelli A; Semeraro N; Gresele P Hepatology; 2003 Jul; 38(1):230-7. PubMed ID: 12830006 [TBL] [Abstract][Full Text] [Related]
55. The antifibrinolytic effects of carbon monoxide-releasing molecule-2 are fibrin and alpha2-antiplasmin dependent. Nielsen VG Blood Coagul Fibrinolysis; 2010 Sep; 21(6):584-7. PubMed ID: 20683324 [TBL] [Abstract][Full Text] [Related]
56. Measuring fibrinolysis: from research to routine diagnostic assays. Longstaff C J Thromb Haemost; 2018 Apr; 16(4):652-662. PubMed ID: 29363269 [TBL] [Abstract][Full Text] [Related]
57. Southern copperhead venom enhances tissue-type plasminogen activator induced fibrinolysis but does not directly lyse human plasma thrombi. Nielsen VG J Thromb Thrombolysis; 2016 Jul; 42(1):33-7. PubMed ID: 26407681 [TBL] [Abstract][Full Text] [Related]
58. Thrombin-activatable fibrinolysis inhibitor in hypothyroidism and hyperthyroxinaemia. Verkleij CJ; Stuijver DJ; van Zaane B; Squizzato A; Brandjes DP; Büller HR; Meijers JC; Gerdes VE Thromb Haemost; 2013 Feb; 109(2):214-20. PubMed ID: 23197299 [TBL] [Abstract][Full Text] [Related]
59. Hydroxyethyl starch enhances fibrinolysis in human plasma by diminishing alpha2-antiplasmin-plasmin interactions. Nielsen VG Blood Coagul Fibrinolysis; 2007 Oct; 18(7):647-56. PubMed ID: 17890952 [TBL] [Abstract][Full Text] [Related]